A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study
arthritis-research.biomedcentral.com
RA outcomes better with tocilizumab than TNFi as first biologic therapy
Patients with rheumatoid arthritis who initiate tocilizumab as their first biologic therapy after failure…
medwirenews.com
IL-6 Inhibitor Kevzara Granted FDA Approval for Rheumatoid Arthritis
rheumnow.com
Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs
MADRID , June 14, 2017 /PRNewswire/ — Sirukumab Phase 3 Data Presented at the Annual European Congress of Rheumatology (EULAR ) 2017 a lso Show Significant Improve ment in Quality of Life Measures Janssen-Cilag …
finance.yahoo.com
J&J arthritis drug sirukumab raises safety concerns: FDA staff
There were more deaths in patients taking Johnson &…
reuters.com